Dimeric FAP-binding radiopharmaceuticals such as DOTAGA.(SA.FAPi)2 likewise show substantially longer tumor residence and higher absorbed tumor doses than monomeric analogues [21,50,51,52], with corresponding improvements in clinical outcomes. Here, FAP is linked to neoplasm.